Advance Program Stability By Building Cryopreservation Into The System, Not Around It

Cryopreservation is often adopted early to manage scheduling gaps between collection and manufacturing, but inconsistent methods across sites can quietly introduce variability that persists throughout development. This article explores why treating cryopreservation as an integrated process—rather than an add-on—matters as programs mature. While early-stage studies can tolerate variation, later phases require frozen material to behave consistently across locations, timelines, and batches. Informal or site-specific practices may create documentation challenges when programs prepare for regulatory filings, even if safety is not compromised. By embedding standardized, automated, and GMP-aligned cryopreservation workflows from the outset, teams can reduce operational drift and improve reproducibility. The article also highlights the advantages of integrating cryopreservation within an end-to-end supply chain framework, enabling consistent controls as programs scale geographically. Building cryopreservation into the system early helps advanced therapy programs maintain stability, avoid costly rework, and support smoother transitions from early development to clinical and regulatory milestones.